salt form of semaglutide Weight Loss Treatment: GLP-1 Care Plan Structure and dynamics of semaglutide-
Description
The FDA label includes a boxed warning regarding thyroid C-cell tumors, contraindicating use in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
Increasing the dose, switching to a different medication or combining approaches can sometimes lead to additional progress
PMCID: PMC5501083
Avoid the inner thigh, where blood vessels and nerves are closer to the surface
